Forte Biosciences, Inc. (FBRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
FBRX currently has 13.9M outstanding shares. with significant dilution risk as 34M authorized shares could dilute existing holders by 244.4%. The company has significantly diluted shareholders by 801.09% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jun 02, 2026 |
S-3 filing: The company filed an S-3 shelf registration statement to offer up to $500,000,000 in various securities including common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, and purchase contracts. |
14M | 34M |
| May 11, 2026 |
10-Q filing | 13.9M shares outstanding |
14M | 34M |
| Mar 31, 2026 |
10-K filing | 13.9M shares outstanding |
14M | 34M |
| Nov 14, 2025 |
10-Q filing | 12.5M shares outstanding |
13M | 35M |
| Aug 14, 2025 |
10-Q filing | 12.4M shares outstanding |
12M | 35M |
| May 15, 2025 |
10-Q filing | 6.6M shares outstanding |
6.6M | 41M |
| Mar 28, 2025 |
S-3 filing: Forte Biosciences, Inc. files an S-3 shelf registration statement for the potential offering of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, and units, with an aggregate offering price not to exceed $300,000,000. |
1.5M | 46M |
| Mar 28, 2025 |
10-K filing | 6.6M shares outstanding |
6.6M | 41M |
| Dec 13, 2024 |
S-3 filing: Forte Biosciences, Inc. is offering 9,546,944 shares of common stock for resale by selling stockholders. |
1.5M | 46M |
| Nov 14, 2024 |
10-Q filing | 1.5M shares outstanding |
1.5M | 37M |
| Aug 14, 2024 |
10-Q filing | 36.5M shares outstanding |
37M | 1.9M |
| May 13, 2024 |
10-Q filing | 36.4M shares outstanding |
36M | 1.9M |
| Mar 18, 2024 |
10-K filing | 36.4M shares outstanding |
36M | 2M |
| Nov 13, 2023 |
10-Q filing | 36.3M shares outstanding |
36M | 2M |
| Aug 29, 2023 |
S-3 filing: Filing relates to the offer and resale from time to time of up to 24,856,250 shares of common stock of Forte Biosciences, Inc. by the selling stockholders. |
36M | 2.1M |
| Aug 14, 2023 |
10-Q filing | 36.3M shares outstanding |
36M | 0 |
| May 15, 2023 |
10-Q filing | 21.0M shares outstanding |
21M | 0 |
| Mar 31, 2023 |
10-K filing | 21.0M shares outstanding |
21M | 0 |
| Nov 14, 2022 |
10-Q filing | 18.9M shares outstanding |
19M | 0 |
| Aug 15, 2022 |
10-Q filing | 20.3M shares outstanding |
20M | 0 |
| May 16, 2022 |
10-Q filing | 14.8M shares outstanding |
15M | 0 |
| Mar 31, 2022 |
10-K filing | 14.8M shares outstanding |
15M | 0 |
| Nov 08, 2021 |
10-Q filing | 14.8M shares outstanding |
15M | 0 |
| Aug 16, 2021 |
10-Q filing | 14.1M shares outstanding |
14M | 0 |
| May 28, 2021 |
S-3 filing: Forte Biosciences, Inc. files an S-3 shelf registration to offer common stock, preferred stock, debt securities, depositary shares, subscription rights, and purchase contracts, up to an aggregate offering price of $300,000,000. |
14M | 0 |
| May 10, 2021 |
10-Q filing | 13.5M shares outstanding |
14M | 0 |
| Mar 16, 2021 |
10-K filing | 13.5M shares outstanding |
14M | 0 |
| Nov 09, 2020 |
10-Q filing | 12.8M shares outstanding |
13M | 0 |
| Aug 10, 2020 |
10-Q filing | 11.2M shares outstanding |
11M | 0 |
| Apr 23, 2020 |
10-Q filing | 23.9M shares outstanding |
24M | 0 |
| Feb 27, 2020 |
10-K filing | 23.9M shares outstanding |
24M | 0 |